Global Liposomal bupivacaine Market Size, Share and Trends Analysis Report, By Surgery (Hemorrhoids, Bunionectomy, Others) and By Application (Veterinary and Humans), Forecast (2022-2028)

The global liposomal bupivacaine market is anticipated to grow at a significant CAGR during the forecast period (2022-2028). Liposomal bupivacaine is used in the surgical site to produce local postoperative analgesia for cranial cruciate ligament surgery in dogs and local infiltration for pain relief after bunionectomy and haemorrhoidectomy. The global liposomal bupivacaine market is growing due to the increasing surgical procedures to remove hemorrhoids globally. According to the US National Library of Medicine in July 2021, Hemorrhoidal disease is a common disorder requiring surgical intervention in around 10% of cases. Several sources estimate that the incidence of symptomatic patients in the US is 4.4%, with patients between the ages of 45 to 65 years old being most affected. The increasing number of bunion surgery globally is also boosting the market growth as this drug is used to relieve pain after bunion surgery.

The market players are also contributing significantly to the growth of the market by the adoption of various strategies including mergers and acquisitions, geographical expansion, partnerships, collaborations, and new drug launches, to stay competitive in the market. For instance-

• In June 2021, Pacira Pharmaceuticals, Inc. announced its distribution agreement with Eurofarma for the development and commercialization of EXPAREL in Latin America.
• in June 2021, Eurofarma launched EXPAREL, an injectable suspension of liposomal bupivacaine, a medicine indicated for the control of postoperative pain. The company had received approval for this injectable suspension from USFDA in March 2021, for the treatment of pediatric patients.
• In May 2021, Heron Therapeutics, Inc. received USFDA approval for a post-operative painkiller Zynrelef that combines a generic and widely used anesthetic called bupivacaine with a low dose of the anti-inflammatory medicine meloxicam to treat pain in patients for as long as 72 hours after a bunionectomy, hernia repair or knee replacement surgery.
• In June 2019, Elanco Animal Health received USFDA’s Center for Veterinary Medicine approval for NOCITA bupivacaine liposome injectable suspension in 20ml and 10 ml vials to control pain in veterinary patients for up to 72 hours following certain canine and feline surgeries.

Market Coverage

• The market number available for – 2022-2028
• Base year- 2021
• Forecast period- 2022-2028
• Segment Covered-
  • By Surgery
  • By Application
• Regions Covered-
  • North America
  • Europe
  • Asia-Pacific
  • Rest of the World
• Competitive Landscape- Pacira Pharmaceuticals, Inc. and Eurofarma among others.

Key questions addressed by the report

• What is the market growth rate?
• Which segment and region dominate the market in the base year?
• Which segment and region will project the fastest growth in the market?
• How has COVID-19 impacted the market?
  • Deviation from the pre-COVID-19 forecast
  • Most affected region and segment
• Who is the leader in the market?
• How players are addressing challenges to sustain growth?
• Where is the investment opportunity?

Global Liposomal Bupivacaine Market Report by Segment

By Surgery

• Hemorrhoids
• Bunionectomy

By Application

• Humans
• Veterinary

Global Liposomal Bupivacaine Market Report by Region

North America

• United States
• Canada

Europe

• UK
• Germany
• Italy
• Spain
• France
• Rest of Europe

Asia-Pacific

• China
• India
• Japan
• Rest of Asia-Pacific

Rest of the World

• Latin America
• Middle East & Africa